Proceeds from collaborators Proceeds from Collaborators Professional fee accruals Accrued Professional Fees, Current Registration Statement [Axis] Registration Statement [Axis] Registration Statement Range [Domain] Statistical Measurement [Domain] Segment information Segment Reporting, Policy [Policy Text Block] Total current assets Assets, Current Research and development Research and Development Expense Genevant Genevant Sciences Corporation [Member] Genevant Sciences Corporation [Member] Net change in operating items: Increase (Decrease) in Operating Capital [Abstract] Revenue from Contract with Customer [Abstract] Cash Equivalents, Fair Value Disclosure Cash Equivalents, Fair Value Disclosure Cash Equivalents, Fair Value Disclosure Investment, Name [Domain] Investment, Name [Domain] Entity Filer Category Entity Filer Category Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Investments, Debt and Equity Securities [Abstract] Contingent consideration Fair value of contingent consideration Liability at beginning of the period Liability at end of the period Business Combination, Contingent Consideration, Liability, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Net loss attributable to common shareholders per share Earnings Per Share, Policy [Policy Text Block] Effect of foreign exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Trade accounts payable Accounts Payable, Trade, Current Equity Method Investments and Joint Ventures [Abstract] Investment, Name [Axis] Investment, Name [Axis] Purchase of investments in marketable securities Payments to Acquire Investments Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Total other income Nonoperating Income (Expense) Nov 2021 Registration Stmt Nov 2021 Registration Stmt [Member] Nov 2021 Registration Stmt Deferred license revenue, current Deferred Revenue, Current Shareholders’ equity Equity [Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Issuance of common shares pursuant to the Open Market Sale Agreement Proceeds from issuance of shares under the agreement Proceeds from Issuance of Common Stock Effective annual interest rate on royalty liability Effective Annual Interest Rate Of Royalty Liability Effective Annual Interest Rate Of Royalty Liability Class of Stock [Axis] Class of Stock [Axis] Investment in Genevant Equity Method Investments and Joint Ventures Disclosure [Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Issuance of common shares pursuant to exercise of ESPP Proceeds from Stock Plans Investments in marketable short-term securities Debt Securities, Available-for-Sale, Current October 2021 Prospectus Supplement October 2021 Prospectus Supplement [Member] October 2021 Prospectus Supplement Ownership [Axis] Ownership [Axis] Debt Securities, Unrealized Gain (Loss) Debt Securities, Unrealized Gain (Loss) Short Term Marketable Securities Investments in marketable securities, current [Member] Investments in marketable securities, current Issuance of common shares upon vesting of RSUs Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Nature of business and future operations Nature of Operations [Text Block] Depreciation Depreciation, Depletion and Amortization Customer [Axis] Customer [Axis] Realized gains or losses Debt Securities, Realized Gain (Loss) Accounts payable and accrued liabilities Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Current liabilities: Liabilities, Current [Abstract] Statement of Financial Position [Abstract] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Subsequent Event Type [Domain] Subsequent Event Type [Domain] Enantigen's Selling Shareholders Enantigen's Selling Shareholders [Member] Enantigen's Selling Shareholders Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Cash Investments and Cash Diluted (in USD per share) Earnings Per Share, Diluted Change in deferred license revenue Increase (Decrease) in Deferred Revenue Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Cumulative Collaboration Revenue Recognized Contract with Customer, Liability, Revenue Recognized Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Fair value measurements Fair Value Measurement, Policy [Policy Text Block] Issuance of common shares pursuant to ESPP Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Issuance of common shares pursuant to the Open Market Sale Agreement Stock Issued During Period, Value, New Issues, Open Market Sale Agreement Stock Issued During Period, Value, New Issues, Open Market Sale Agreement Premium on closing stock price ($ paid) Premium on closing stock price ($ paid) Premium on closing stock price ($ paid) Weighted average exercise price (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Investments in marketable securities, current Investments, Fair Value Disclosure Level 2 Fair Value, Inputs, Level 2 [Member] Net loss Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Non-cash interest expense Non Cash Interest Expense Related To Sale Of Future Royalties Non Cash Interest Expense Related To Sale Of Future Royalties Fair Value Disclosures [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common Stock, Value, Subscriptions Expired Common Stock, Value, Subscriptions Expired Common Stock, Value, Subscriptions Expired One-Time Upfront Cash Payment One-Time Upfront Cash Payment [Member] One-Time Upfront Cash Payment Other Liabilities Disclosure [Line Items] Other Liabilities Disclosure [Line Items] Other Liabilities Disclosure [Line Items] Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Gross proceeds from sale of royalty interest. before advisory fees Gross Proceeds From Royalty Interest Sold Gross Proceeds From Royalty Interest Sold Royalty interest sold, annual revenue threshold of highest tier Annual Revenue Threshold Annual Revenue Threshold Long Term Marketable Securities Investments in marketable securities, noncurrent [Member] Investments in marketable securities, noncurrent Jefferies LLC Jefferies LLC [Member] Jefferies LLC Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Investments in marketable securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Stockholders’ equity Equity, Attributable to Parent [Abstract] Gross Unrealized Loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Total deferred license revenue Contract with Customer, Liability Issuance of common shares pursuant to exercise of options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Document Fiscal Period Focus Document Fiscal Period Focus Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc [Member] Alnylam Pharmaceuticals, Inc Research and development accruals Accrued Research And Development Research and development accruals Aggregate sale price of common shares under agreement Common Stock, Value, Subscriptions Antidilutive Securities [Axis] Antidilutive Securities [Axis] Recovery of direct costs Recovery of Direct Costs Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Jan 2020 Prospectus Supplement Jan 2020 Prospectus Supplement [Member] Jan 2020 Prospectus Supplement Significant accounting policies Significant Accounting Policies [Text Block] Common Shares Common Stock [Member] Level 1 Fair Value, Inputs, Level 1 [Member] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Liability related to sale of future royalties Net liability related to sale of future royalties - beginning balance Net liability related to sale of future royalties - ending balance Liability Related To Sale Of Future Royalties, Noncurrent Liability Related To Sale Of Future Royalties, Noncurrent Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Ownership interest in equity method investment (as a percentage) Equity Method Investment, Ownership Percentage Potential milestone payments Potential Milestone Payments Represents the potential milestone payments amount. Document Fiscal Year Focus Document Fiscal Year Focus Marketable Securities [Table] Marketable Securities [Table] Options granted during period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Summary of collaborations Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Entity Small Business Entity Small Business Amortization of other deferred charges Amortization of Other Deferred Charges Contingencies and Commitments [Table] Contingencies and Commitments [Table] Minimum Minimum [Member] Local Phone Number Local Phone Number Number of wholly-owed subsidiaries Wholly Owned Subsidiaries Included in Financial Statements Represents the number of wholly owned subsidiaries included in the reporting of the financial statements. Accounts receivable Increase (Decrease) in Accounts Receivable Property and equipment, net of accumulated depreciation of $12,256 (December 31, 2023: $11,900) Property, Plant and Equipment, Net Sale Agreement Sale Agreement [Member] Sale Agreement Measurement Frequency [Axis] Measurement Frequency [Axis] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Lease liability, non-current Operating Lease, Liability, Noncurrent Development and regulatory milestones payment per licensed compound series, maximum License Agreement Maximum Development And Regulatory Milestone Payments Per License License Agreement, Maximum Development and Regulatory Milestone Payments Per License Total Liabilities, Fair Value Disclosure Royalty guarantees commitments percentage Royalty Guarantees Commitments Percentage Represents the royalty guarantees commitments percentage. Foreign exchange gain Gain (Loss), Foreign Currency Transaction, before Tax Number of royalty entitlements Royalty Entitlements Royalty Entitlements Non-cash royalty revenue Non-Cash Royalty [Member] Non-Cash Royalty Non-cash royalty revenue Liability From Sale Of Future Royalties, Non Cash Royalty Income Liability From Sale Of Future Royalties, Non Cash Royalty Income Marketable securities Marketable Securities [Table Text Block] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Sub-licensing revenue percentage Sub-licensing revenue Percentage Sub-licensing revenue Percentage Contingencies and commitments Commitments and Contingencies Disclosure [Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Deficit Retained Earnings [Member] Accrued investment income receivable Accrued Investment Income Receivable Schedule of stock based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Net accretion and amortization of investments in marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Issuance of common shares pursuant to the Open Market Sale Agreement (in shares) Stock Issued During Period, Shares, New Issues, Open Market Sale Agreement Stock Issued During Period, Shares, New Issues, Open Market Sale Agreement Total liabilities and stockholders’ equity Liabilities and Equity Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Ownership [Domain] Ownership [Domain] Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Basic (in USD per share) Earnings Per Share, Basic Right of use asset Operating Lease, Right-of-Use Asset Issuance of common shares pursuant to ESPP Stock Issued During Period, Value, Employee Stock Purchase Plan Accounting Policies [Abstract] Sale of Stock [Domain] Sale of Stock [Domain] Number of shares issued under agreement (in sales) Sale of Stock, Number of Shares Issued in Transaction Payables and Accruals [Abstract] Revenues Revenues Schedule of accounts payable and accrued liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Product and Service [Domain] Product and Service [Domain] Payroll accruals Accrued Payroll Current Accrued Payroll Current Weighted average number of common shares Weighted Average Number Of Common Shares [Abstract] Weighted average number of common shares Non-cash royalty revenue Non-cash royalty revenue Non Cash Royalty Revenue Related To Sale Of Future Royalties Non Cash Royalty Revenue Related To Sale Of Future Royalties Non Cash Royalty Revenue Related To Sale Of Future Royalties Entity Address, City or Town Entity Address, City or Town Research and development Research and Development Expense [Member] INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Income taxes paid Income Taxes Paid Anti-dilutive common shares excluded from calculation of loss per common share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Principles of consolidation Consolidation, Policy [Policy Text Block] Restricted stock units granted during period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Document Quarterly Report Document Quarterly Report Interest expense Interest Expense Schedule of changes in fair value of contingent consideration Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Document Transition Report Document Transition Report General and administrative General and Administrative Expense [Member] US government agency bonds US Government Agency Bonds [Member] US Government Agency Bonds [Member] Future royalty payments Royalty Payable Represents the royalty payable. Stockholders' Equity Note [Abstract] Fair Value Investments in marketable securities, fair value Debt Securities, Available-for-Sale Debt Securities, Available-for-Sale [Abstract] Debt Securities, Available-for-Sale [Abstract] Entity File Number Entity File Number Other deferred costs, gross Other Deferred Costs, Gross Arbutus Plans Arbutus Plans [Member] Arbutus Plans [Member] Lease liability, current Operating Lease, Liability, Current Revenue from collaborations and licenses License [Member] Gross Unrealized Gain Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Issuance of common shares pursuant to ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Other Liabilities Disclosure [Abstract] Entity Shell Company Entity Shell Company Investments in marketable securities, non-current Long-Term Investments Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Recent accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Vaccitech Barinthus [Member] Barinthus Counterparty Name [Domain] Counterparty Name [Domain] Other liabilities Increase (Decrease) in Other Operating Liabilities Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents US Government Securities, at Carrying Value US Government Securities, at Carrying Value Interest income Investment Income, Interest Additional paid-in capital Additional Paid in Capital Common shares, shares issued (in shares) Common Stock, Shares, Issued Disposition of investments in marketable securities Proceeds from Sale, Maturity and Collection of Investments Security Exchange Name Security Exchange Name Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Total Assets, Fair Value Disclosure Long-term debt Long-Term Debt Issuance of common shares pursuant to exercise of stock options Proceeds from Stock Options Exercised Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Jan 2020 Registration Stmt Jan 2020 Registration Stmt [Member] Jan 2020 Registration Stmt Collaborations, contracts and licensing agreements Collaborative Arrangement Disclosure [Text Block] Employee Stock Option Employee Stock Option [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Jan 2020 Oct 2020 and Nov 2021 Registration Stmts Jan 2020 Oct 2020 and Nov 2021 Registration Stmts [Member] Jan 2020 Oct 2020 and Nov 2021 Registration Stmts [Member] Non-cash interest expense Liability From Sale Of Future Royalties, Non Cash Interest Expense Liability From Sale Of Future Royalties, Non Cash Interest Expense Entitlement of royalties to be received Royalty Interest Sold, Maximum Royalties For Buyer Royalty Interest Sold, Maximum Royalties For Buyer Financial Instruments, Owned, US Government and Agency Obligations, at Fair Value Financial Instruments, Owned, US Government and Agency Obligations, at Fair Value Maximum Maximum [Member] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Cash Equivalents, at Carrying Value Cash Equivalents, at Carrying Value Document Type Document Type Share price (in USD per share) Share Price Acuitas Therapeutics, Inc. Acuitas Therapeutics Inc. [Member] Acuitas Therapeutics Inc. Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Change in fair value of contingent consideration Increase (decrease) in fair value of contingent consideration Change in fair value of liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Basis of presentation Basis of Accounting, Policy [Policy Text Block] Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] Document Period End Date Document Period End Date Issuance of common shares pursuant to the Open Market Sale Agreement Proceeds from Issuance of Common Stock, Open Market Sale agreement Proceeds from Issuance of Common Stock, Open Market Sale agreement Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Accumulated depreciation of property and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Business Acquisition [Axis] Business Acquisition [Axis] Assets and liabilities measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Entity Central Index Key Entity Central Index Key Subsequent Event Subsequent Event [Member] Liabilities Liabilities, Fair Value Disclosure [Abstract] Allocated share-based compensation expense Share-Based Payment Arrangement, Expense Transaction costs on sale of royalties Transaction Costs Related To Sale Of Future Royalties Transaction Costs Related To Sale Of Future Royalties Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Statement [Abstract] ONPATTRO ONPATTRO, global net sales [Member] ONPATTRO, global net sales Title of 12(b) Security Title of 12(b) Security Fair value measurements Fair Value Disclosures [Text Block] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Collaborations and licenses Collaboration And Contracts [Member] Collaboration And Contracts [Member] Noncontrolling interest, ownership percentage by noncontrolling owners Subsidiary, Ownership Percentage, Noncontrolling Owner Development and regulatory milestones payment per royalty, maximum License Agreement Maximum Development And Regulatory Milestone Payments Per Royalty License Agreement Maximum Development And Regulatory Royalty Payment per Royalty Grant date fair value (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Fair Value, Liabilities Measured on Recurring Basis [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis [Roll Forward] Class of Stock [Line Items] Class of Stock [Line Items] Entity [Domain] Entity [Domain] Contingencies and Commitments [Line Items] Contingencies and Commitments [Line Items] Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] Money market Money Market Funds [Member] Entity Tax Identification Number Entity Tax Identification Number Qilu Pharmaceutical Co, LTD. Qilu Pharmaceutical Co, LTD. [Member] Qilu Pharmaceutical Co, LTD. Equity investment Equity Method Investments Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Range [Axis] Statistical Measurement [Axis] Assets Assets, Fair Value Disclosure [Abstract] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Oct 2020 Registration Stmt Oct 2020 Registration Stmt [Member] Oct 2020 Registration Stmt Non-cash items: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] US government bonds US Government Bonds [Member] US Government Bonds [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Schedule of deferred collaborations and contracts revenue Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Money Market Funds, at Carrying Value Money Market Funds, at Carrying Value Deficit Retained Earnings (Accumulated Deficit) Commitments and Contingencies Disclosure [Abstract] Revenue from collaborations and licenses and Deferred Revenue Revenue from Contract with Customer [Policy Text Block] Operating expenses Operating Expenses [Abstract] Schedule of activity related to the net liability from inception of the Agreement Liabilities Related To Sale Of Future Royalties Roll Forward [Table Text Block] Liabilities Related To Sale Of Future Royalties Roll Forward US corporate bonds US Corporate Bonds [Member] US Corporate Bonds Acquisition of property and equipment Payments to Acquire Property, Plant, and Equipment Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Additional Paid-In Capital Additional Paid-in Capital [Member] Unrealized gain on available-for-sale securities Debt Securities, Available-for-Sale, Unrealized Gain (Loss) Current assets: Assets, Current [Abstract] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total assets Assets Entity Address, State or Province Entity Address, State or Province Counterparty Name [Axis] Counterparty Name [Axis] Cover [Abstract] OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Royalty interest, % interest Royalty interest, Percent interest Royalty interest, % interest OMERS OMERS [Member] OMERS Recurring Fair Value, Recurring [Member] Unrealized gain on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common shares, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Mar 2021 Prospectus Supplement Agreement Mar 2021 Prospectus Supplement Agreement [Member] Prospectus Supplement - Open Market Sale Agreement Mar 2021 Revenue, remaining performance obligation, amount Revenue, Remaining Performance Obligation, Amount Costs related to collaboration Other Cost and Expense, Operating Total operating expenses Operating Expenses Increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Sale of Stock [Axis] Sale of Stock [Axis] Equity Component [Domain] Equity Component [Domain] Class of Stock [Domain] Class of Stock [Domain] Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities US treasury bills US Treasury Bill Securities [Member] Registration Statement [Domain] Registration Statement [Domain] Registration Statement [Domain] Customer [Domain] Customer [Domain] Debt securities, available-for-sale, unrealized loss Position, number of positions Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Liability Related To Sale Of Future Royalties [Roll Forward] Liability Related To Sale Of Future Royalties [Roll Forward] Liability Related To Sale Of Future Royalties [Roll Forward] Sale of future royalties Liabilities Related To Sale Of Future Royalties [Text Block] Liabilities Related To Sale Of Future Royalties Loss from operations Operating Income (Loss) March 2022 Prospectus Supplement March 2022 Prospectus Supplement [Member] March 2022 Prospectus Supplement Premium on closing stock price (as a percent) Premium on Closing Stock Price Premium on Closing Stock Price Total liabilities Liabilities Aug 2020 Prospectus Supplement Aug 2020 Prospectus Supplement [Member] Aug 2020 Prospectus Supplement Arbutus Inc. Arbutus Inc. [Member] Arbutus Inc. [Member] Revenue Revenues [Abstract] Cash and Cash Equivalents Cash and Cash Equivalents [Member] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Change in fair value of contingent consideration Increase (Decrease) In Fair Value Of Contingent Consideration Liability Increase (Decrease) In Fair Value Of Contingent Consideration Liability Revenue from External Customers by Products and Services [Table] Revenue from External Customers by Products and Services [Table] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Statement [Line Items] Statement [Line Items] Yankee bonds Yankee Bonds [Member] Yankee Bonds Plan Name [Axis] Plan Name [Axis] Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Loss per share Earnings Per Share [Abstract] Issued and outstanding: 180,192,227 (December 31, 2023: 169,867,414) Common Stock, Value, Issued General and administrative General and Administrative Expense Arbutus Biopharma Corp Arbutus Biopharma Corp [Member] Arbutus Biopharma Corp Bona fide collaboration Percentage Bona fide collaboration Percentage Bona fide collaboration Percentage Organization, Consolidation and Presentation of Financial Statements [Abstract]